CS-4771 Phase 1 study - A randomized, double-blind, placebo-controlled, continuous IV infusion for 96 hours, ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-4771 in Japanese healthy subjects -
Latest Information Update: 15 Jun 2016
At a glance
- Drugs CS 4771 (Primary)
- Indications Sepsis
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 Jun 2016 New trial record